Liposome Co. anticancer agents
Executive Summary
IND reviews for liposomal formulations of doxorubicin (TLC-DOX99) and a platinum derivative (TLC-PLAT23) have been completed by FDA and human testing in the U.S. will begin "shortly" at Roswell Park Memorial Institute and M.D. Anderson Hospital and Tumor Institute. Princeton, N.J.-based Liposome Company announced the status of trials in a Feb. 29 press release.